The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2022 Hereditary Hemorrhagic Telangiectasia (HHT) Center. The purpose of the program is to reduce morbidity and mortality associated with hereditary hemorrhagic telangiectasia by funding a national center to: 1) expand access to and coordination of care for HHT patients; and 2) develop a de-identified, aggregate data collection registry to better understand this rare disease and treatment outcomes.